ClinicalTrials.gov
ClinicalTrials.gov Menu

Molecular Genetic and Pathological Studies of Anal Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00267787
Recruitment Status : Terminated
First Posted : December 21, 2005
Last Update Posted : December 10, 2018
Sponsor:
Information provided by (Responsible Party):
Stanford University

Brief Summary:
Study the Genetics of Anal Cancer

Condition or disease Intervention/treatment
Rectal Cancer Colon Cancer Colonic Neoplasms Anal Cancer Other: genetic analysis

Detailed Description:
To determine the status of previously identified anal cancer molecular markers and any correlations with outcome as well as to discover new molecular biomarkers through correlating molecular data with clinical outcome. Study of tissue samples and cells from biopsies of your lesion and blood sample. We hope to learn the role genes and proteins may play in the development of anal cancer. Experiments will be performed using this tissue and blood, include analysis of DNA, analysis of RNA expression levels, analysis of protein levels of important gene products, and development of tissue culture cell lines.

Study Type : Observational
Actual Enrollment : 7 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Molecular Genetic and Pathological Studies of Anal Tumors
Study Start Date : September 2004
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anal Cancer


Intervention Details:
  • Other: genetic analysis
    standard of care


Primary Outcome Measures :
  1. Genetic analysis of blood sample as well as tissues , will provide us with any possible tumor marker for a better prognostic indicator. [ Time Frame: Annual assessment. ]

Biospecimen Retention:   Samples With DNA
whole blood


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Adult patients with anal cancer or high risk for anal cancer refered to Stanford.
Criteria

Inclusion Criteria:Inclusion Criteria:

  • Patients with anal tumors
  • Undergoing surgery for elective colon and rectal surgery

Exclusion Criteria:No other patients other than adult patients with anal cancer or high risk for anal cancer refered to Stanford will be enrolled to the study. No Children will be included to the study


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00267787


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Mark Lane Welton Stanford University

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00267787     History of Changes
Other Study ID Numbers: ANAL0001
95340 ( Other Identifier: Stanford University Alternate IRB Approval Number )
ANAL0001 ( Other Identifier: Stanford University )
14037 ( Other Identifier: Stanford IRB )
First Posted: December 21, 2005    Key Record Dates
Last Update Posted: December 10, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Anus Neoplasms
Colonic Neoplasms
Rectal Neoplasms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Anus Diseases
Rectal Diseases
Colonic Diseases